Expanding our understanding of Post COVID-19 condition
Daniel Altmann

Professor Altmann is Professor of Immunology at Imperial College London, where he heads a lab at the Hammersmith Hospital Campus. Professor Altmann has acted in a range of roles during the pandemic in providing advice to policy-makers, including the House of Commons and House of Lords Science Committees. He has served for the past 20 years as Editor across a number of medical journals including Oxford Open Immunology, Immunology and Vaccine. He is a trustee of the Medical Research Foundation and a board member for the African Research Excellence Fund. He previously headed up strategy on infection, immunity and population health at the Wellcome Trust. His research interests focus on the immunology of infectious diseases including severe bacterial infections, SARS-CoV-2, Zika virus and Chikungunya virus, as well as a long record in autoimmune research. His lab uses tools such as the analysis of HLA polymorphism and the molecular immunology of T cell and NK cells subsets and antigen responses to characterise innate and adaptive immunity.

Shinjini Bhatnagar

Professor Shinjini Bhatnagar is a physician scientist who worked with the Department of Pediatrics at the All India Institute of Medical Sciences (AIIMS) for 25 years as a paediatric gastroenterologist and research scientist. Her group's hypothesis driven research led to the introduction of the modified low osmolarity ORS and zinc in treatment for childhood diarrhoea and diagnostic tests for celiac disease. She is currently Professor of Eminence at the Translational Health Science and Technology Institute, an autonomous institute of the Department of Biotechnology (DBT) (Government of India). She now leads large interdisciplinary research studies that bridge classical clinical research and modern biology to find solutions for diseases with public health importance. Two important programmes she is coordinating are Garbh-Ini (an interdisciplinary group for advanced research on birth outcome – DBT India initiative) and evaluation of zinc as an adjunct to antimicrobial therapy for young infant sepsis. She is a fellow of three national academies: National Academy of Sciences, National Academy of Medical Sciences and Indian Nations Science Academy.
Bin Cao

Dr Bin Cao is Vice President of China-Japan Friendship Hospital, Director of Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital; Vice Director of the National Center for Respiratory Medicine; Vice President of the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; Member of the Chinese Academy of Medical Sciences, Yangtze River Distinguished Professor of Ministry of Education; Professor of Capital Medical University; Professor of Tsinghua University-Peking University Joint Center for Life Sciences. He is President-elect of the Chinese Thoracic Society; Associate Editor of Clinical Respiratory Journal; Editorial advisory board member of EBioMedicine; and committee member of the Antiviral Group (AVG) of the International Society of Influenza and Other Respiratory Virus Diseases (ISIRV).

As a senior expert in respiratory infections, his research mainly focuses on the current key issues concerning acute respiratory infections and emerging infectious diseases, including: epidemiology, clinical characteristics, and treatment of viral pneumonia; molecular and cellular basis of the pathogenesis of influenza and COVID-19; and diagnosis and treatment strategy and drug resistance of infections by drug-resistant pathogens. He has published more than 200 peer-reviewed articles and reviews, among which 8 representative papers are published in the Lancet or NEJM.


He has been honoured with the title of National Outstanding Individual in the Fight against COVID-19 in 2020, Distinguished Respiratory Academic Contribution Award in 2018, National Award for Science and Technology Progress (Grand Prize) in 2017, Yangtze River Distinguished Professor of Ministry of Education in 2015, and Wu JiePing-Paul Janssen Medical-Pharmaceutical Award in 2014.

Gail Carson

Dr Gail Carson graduated from Edinburgh Medical School in 1994 and completed her infectious diseases training in Manchester before taking up her first consultant post with the Health Protection Agency at Porton Down. In this role she acted as a liaison between the special pathogens laboratory and the NHS medical teams. In 2000 she responded to the Ebola outbreak in Uganda and since then has been involved with the Global Outbreak Alert & Response Network (GOARN); currently as Deputy Chair. In 2003 she was seconded to WHO Geneva as part of the SARS response. Responding to the lack of clinical research done during the 2009/2010 influenza pandemic she moved to the University of Oxford to set up the International Severe Acute Respiratory & emerging Infection Consortium (ISARIC). This is a network of clinical research networks that prepares and responds to epidemics. For the past 6 years she has been the Scientific Secretariat for the epidemic research funders’ consortium GloPID-R and continues to work closely with the WHO.

Hannah Davis

Hannah Davis is a researcher with the Patient-Led Research collaborative, UK, currently focused on researching Long COVID. Previously, she was an independent researcher in data analysis and machine learning, with a focus on modelling worldviews and tools for countering bias in machine learning datasets. She is a public speaker and has spoken at the Library of Congress, Bell Labs, Eyeo Festival, the European Association for Computational Linguistics, among others.
Andrea Lerner
Andrea Lerner is an infectious diseases physician and medical officer in the Office of the Director of the National Institute of Allergy and Infectious Diseases (NIAID), of the National Institutes of Health (NIH). She earned her medical degree from George Washington University in Washington, DC, and completed her internal medicine internship and residency training at Thomas Jefferson University in Philadelphia, Pennsylvania. Following residency training, Dr Lerner practised as a hospitalist physician in San Diego and Baltimore before completing her fellowship in infectious diseases at NIAID, NIH. Her areas of particular interest within infectious diseases include HIV, antimicrobial resistance, and emerging infectious diseases.

Dale M Needham
Dr Needham is Professor of Pulmonary and Critical Care Medicine, and of Physical Medicine and Rehabilitation at the Johns Hopkins University in Baltimore, USA. He is Director of the “Outcomes After Critical Illness and Surgery” (OACIS) Group at Johns Hopkins. Clinically, he is an attending physician in the medical intensive care unit at Johns Hopkins Hospital and Medical Director of the Johns Hopkins Critical Care Physical Medicine and Rehabilitation programme. Dr Needham is Principal Investigator on a number of research grants and has authored more than 350 publications. His research interests include evaluating and improving ICU patients’ long-term physical, cognitive and mental health outcomes, including research in the areas of sedation, delirium, early physical rehabilitation, and knowledge translation and quality improvement.

Carlos A Pardo-Villamizar
Dr Pardo is Professor of Neurology and Pathology (Neuropathology) at Johns Hopkins University School of Medicine. His clinical and research work focuses on the diagnosis and management of neurological, neuroimmune and neuroinfectious disorders. As a clinician, he is dedicated to studies of neuroimmunological and neuroinfectious disorders and serves as Director of the Johns Hopkins Myelitis & Myelopathy Center, a unique specialized centre dedicated to clinical research of spinal cord disorders. He collaborates extensively with different groups around the world and is currently the Principal Investigator (PI) of the Neuroviruses Emerging in the Americas Study (NEAS), a multicentre study funded by NIH and based in Colombia to investigate the role of emerging viral infections and association with neuroinflammatory disorders such as encephalitis, myelitis and Guillain-Barré syndrome. He is the co-PI of the NIH-funded Acute Flaccid Myelitis Natural History to characterize the natural history of this disorder. As a neuroscientist, his translational and laboratory research centres on studies of immunopathogenic mechanisms of neurological disorders, animal models and biomarkers of disease.

Simone Piva
Dr Piva is a graduate from the University of Brescia, Italy. He completed his clinical training in Brescia and is board certified in anaesthesiology and critical care medicine. He completed his research fellowship at Harvard University (2005–2006), where he joined the Center for Blood Research and the Boston Children's Hospital. In 2007 he became a consultant in critical care at Spedali Civili di Brescia University Hospital, Italy. He then joined St Michael's Hospital (University of Toronto) for a clinical fellowship between 2010 and 2011 and gained an MSc in medical statistics in 2017. His main research focuses are intensive care unit acquired weakness (ICU-AW) and diaphragmatic weakness, along with sepsis-associated delirium and neuroinflammation. Recently he won an Italian award on abdominal muscle ultrasound during spontaneous breathing trial. He has published more than 20 papers. In 2018 Dr Piva took up a faculty position at Brescia University Graduate School of Medicine.
Biographies

Marco Rizzi
Dr Rizzi has clinical and specialty training in infectious diseases from the Università degli Studi, Milan, Italy, and the HIV/AIDS Training Program of the International Society for Infectious Diseases, University of California-San Francisco General Hospital. Dr Rizzi is currently Head of the Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, and President of the Committee on Infection Control and Antimicrobial Stewardship. At ASST Papa Giovanni XXIII he is Coordinator of the Surviving COVID-19 project. Dr Rizzi is Infectious Diseases Adjunct Professor at the Medical School, Università Milano Bicocca, Italy, and President (2018–2022) of the Regione Lombardia section of the Italian Society of Infectious & Tropical Diseases (SIMIT).

Regis Goulart Rosa
Critical care physician and researcher in the field of post-intensive care unit outcomes, Hospital Moinhos de Vento, Porto Alegre, Brazil.
WORKING GROUP 1: DEVELOP CLINICAL CASE DEFINITION

CHAIR Margaret Herridge

Margaret S Herridge is Professor of Medicine, Critical Care and Pulmonary Medicine at the University Health Network; Senior Scientist in the Toronto General Research Institute; Director of Research for the Interdepartmental Division of Critical Care Medicine, University of Toronto. She completed her research training at the Channing laboratory/Harvard School of Public Health. Since 1997, her group has completed three cohort studies: 5-year outcomes in survivors of ARDS; 1-year outcomes in survivors of SARS; 2-year outcomes in patients after 7 days of mechanical ventilation and their family caregivers (RECOVER Program – Phase I). Currently, Dr Herridge is co-leading the CIHR-funded CANCOV Program (Canadian Prospective Multi-Centre 1-year Cohort Study of COVID-19 patients and caregivers). She is Director of the RECOVER Clinical and Research Program for patient-and family-centred follow-up care after critical illness and clinical director of the Long-Term Ventilation program – Grace RECOVER Program for Chronic Critical Illness. Dr Herridge has led two editorials and three manuscripts in the NEJM on 1- and 5-year outcomes after ARDS and family caregiver outcomes after prolonged mechanical ventilation and is a frequent international speaker on outcomes after critical illness.

Nisreen Alwan

Dr Nisreen Alwan is an Associate Professor in Public Health at the University of Southampton, UK. During the COVID-19 pandemic, Dr Alwan has advocated the recognition and the quantification of morbidity from COVID-19, having initiated the call to count “Long COVID.” She was awarded an MBE for services to Medicine and Public Health during the COVID-19 pandemic in the Queen’s New Year Honours 2021. She was also named amongst inspiring and influential women from around the world in the BBC 100 Women 2020 list.

Shinjini Bhatnagar

See Speakers

Bin Cao

See Speakers
Biographies

Expanding our understanding of Post COVID-19 condition

Christopher G Chute

Dr Chute is the Bloomberg Distinguished Professor of Health Informatics, Professor of Medicine, Public Health, and Nursing at Johns Hopkins University, and Chief Research Information Officer for Johns Hopkins Medicine. He received his undergraduate and medical training at Brown University, internal medicine residency at Dartmouth, and doctoral training in Epidemiology and Biostatistics at Harvard. He is Board Certified in Internal Medicine and Clinical Informatics, and an elected Fellow of the American College of Physicians, the American College of Epidemiology, HL7, the American Medical Informatics Association, and the American College of Medical Informatics (ACMI), as well as a Founding Fellow of the International Academy of Health Sciences Informatics; he was president of ACMI through 2018. His career has focused on how we can represent clinical information to support analyses and inferencing, including comparative effectiveness analyses, decision support, best evidence discovery, and translational research. He has had a deep interest in semantic consistency, harmonized information models, and ontology. His current research focuses on translating basic science information to clinical practice, and how we classify dysfunctional phenotypes (disease). He became founding Chair of Biomedical Informatics at Mayo Clinic in 1988, retiring from Mayo in 2014, where he remains an emeritus Professor of Biomedical Informatics. He is presently Principal Investigator on a spectrum of high-profile informatics grants from NIH spanning translational science. He has been active on many HIT standards efforts and chaired ISO Technical Committee 215 on Health Informatics and the WHO International Classification of Disease Revision (ICD-11).

Hannah Davis

See Speakers

Francesco Landi

Francesco Landi is Associate Professor of Internal Medicine at the Catholic University of Rome, School of Medicine. He is the chief of the Geriatric Internal Medicine Unit of the Geriatrics Department of the Gemelli University Hospital. He has been a visiting Assistant Professor at Brown University School of Medicine, Department of Community Health. His main research interests are in geriatric assessment, nutritional problems, sarcopenia, models of health services for elderly care, and geriatric pharmaco-epidemiology. Professor Landi serves as a President of the Scientific Committee of the Italian Geriatric Society; is on the editorial board of several international geriatric journals; and is a peer reviewer for numerous international medical journals. He has acted as the Principal Investigator in many multicentre national and international trials. In addition, he is a member of national and international expert groups that work on guidelines in the field of nutrition, sarcopenia and functionality in older adults. Professor Landi has over 350 peer-reviewed original papers in international medical journals, many of which are in the area of frailty and functional status of older people. He is particularly interested in the role of nutrition as part of the integrated care of older adults, and participated in the development of the European consensus on sarcopenia definition and diagnosis. During the last year he has worked on COVID-19 research, especially on "Long COVID-19 symptoms".

Andrea Lerner

See Speakers
Daniel Munblit

Dr Daniel Munblit graduated from a Russian State Medical University in 2003 and then trained at the Moscow Institute of Paediatrics and Child Surgery. Daniel accomplished his PhD research at Imperial College London in 2016. Prior to this, he successfully completed an MSc in Allergy at Imperial College London. His main research focus is the primary prevention of allergic disease in childhood; investigation of associations between early life events, maternal health, nutrition and genotype and subsequent infant health outcomes. During the COVID-19 pandemic he leads two large cohort studies in Moscow, covering adult and paediatric populations. Together with Louise Sigfrid, Daniel serves as a co-chair of ISARIC Global Paediatric Long COVID Working Group. He currently shares his time between Moscow and London, being Professor at the Paediatrics and Paediatric Infectious Disease Department of Sechenov University and Honorary Senior Lecturer, Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College London.

Alessandro Padovani

Professor Padovani is currently Full Professor of Clinical Neurology and Head of the Institute of Clinical Neurology at the Department of Clinical and Experimental Sciences, University of Brescia, Italy. Since 2005, he has been Director of the School of Neurology of the University of Brescia. He has held a variety of national positions, including Secretary of the Italian Society of Neurology (SIN), Vice-President of the Italian PsychoGeriatric Association (AIP). From 2005–2007 he served as an expert in the Dementia Commission of the Ministry of Welfare, and from 2011–2012 at the Research and Development Branch of the Italian Drug Agency (AIFA). He has researched widely in the field of dementia, movement disorders, stroke and neuropsychology, particularly using clinical, cognitive, genetic, neuroimaging and molecular analysis to further understanding of brain function and disease-related processes. During the COVID-19 pandemic, he established a Neurocovid Unit and he is directing different research programmes in the field of neurology and COVID-19. He has published over 700 papers in peer-reviewed international journals and 30 chapters; his H-index is about 68 (WoS).

Sharon Saydah

Sharon Saydah is an epidemiologist and senior scientist at the US Centers for Disease Control and Prevention, Division of Viral Diseases, Respiratory Viruses Branch and Commander in the United States Public Health Service. She received her PhD in epidemiology from Johns Hopkins Bloomberg School of Public Health and joined CDC as an Epidemic Intelligence Service Officer in 2003. She is a leading researcher in clinical and chronic disease epidemiology. Prior to the COVID-19 pandemic, Dr Saydah’s work focused public health research on surveillance of diabetes among youth and young adults along with prevention of diabetes and its complications. She is currently she is serving in the CDC COVID-19 response and leads a team investigating the natural history of SARS-CoV-2 infection, including prospective cohort studies focused on the Post COVID-19 condition.

Juno Simorangkir

“Hello my name is Juan Charles Tuvano or you can simply call me Juno, I’m from Jakarta, Indonesia. I founded Covid Survivor Indonesia as the biggest community for COVID-19 survivors here. We have started our community group since August 2020. Our goal is to provide a place to share experiences and support between the COVID-19 survivors and also to give a proper education about COVID-19 especially around things to do as a survivors. We have a focus in Long Covid where a lot of survivors are still under prolonged symptoms in their recovery trial and we look forward for any treatment to support our life and to support any research for the goodness of all.”
Ramachandran Thiruvengadam

Dr Ramachandran Thiruvengadam is a scientist at the Translational Health Science and Technology Institute, Faridabad, India. He is a paediatrician and medical biochemist by qualification. As a physician-scientist and an investigator in the domain of maternal and child health, his principal research interests lie in the epidemiological understanding and development of clinically translatable solutions for preterm birth and fetal growth restriction. He works on development and validation of clinical prediction models for these outcomes. His research efforts are brought to fruition by building them upon the platform provided by the Garbh-Ini programme, an Interdisciplinary Group for Advanced Research on Birth Outcomes – DBT India Initiative.

Rolf-Detlef Treede

Rolf-Detlef Treede is Professor of Neurophysiology at and deputy managing director of the Mannheim Center for Translational Neuroscience (MCTN) of the Ruprecht-Karls-University Heidelberg in Mannheim, Germany. Between 1988 and 1990 he was Visiting Scientist with the Department of Neurosurgery at the Johns Hopkins Medical Institutions, Baltimore, USA, and from 1992 to 2007 Professor of Neurophysiology at the Institute of Physiology and Pathophysiology of the Johannes Gutenberg University in Mainz, Germany. His wide-ranging interests in the field of pain include the mechanisms and treatment of neuropathic pain, the cortical representation of pain, peripheral nociceptive transduction mechanisms, pain memory, pain assessment by quantitative sensory testing and clinical neurophysiology. He is Vice-President of the German Association of Scientific Medical Societies, Past President of the German Physiological Society, Past-President of the International Association for the Study of Pain, Past Chair of its Special Interest Group on Neuropathic Pain, and Past President of its German chapter. He sits on numerous national and international committees, and has co-authored about 400 publications in journals and books.
WORKING GROUP 2: DEVELOP A CLINICAL CASE DEFINITION; DO DIAGNOSTICS HELP?

CHAIR John Marshall

John Marshall is Professor of Surgery at the University of Toronto, a critical care physician at St Michael’s Hospital, and a Senior Investigator in the Keenan Research Centre for Biomedical Science. He holds the Unity Health Chair in Trauma Research. His academic interests lie in the area of sepsis and life-threatening infection, trauma, and the host innate immune response to these. His laboratory studies the cellular mechanisms that prolong neutrophil survival in critical illness. He has an active clinical research interest in sepsis and ICU-acquired infection, and in the design of clinical trials and outcome measures. He leads CIHR-funded research programmes in novel clinical trial designs and the treatment of post-resuscitation fluid overload in critically ill patients, and has been an active investigator in more than 20 clinical trials. He is the Canadian Principle Investigator for REMAP-CAP, a global platform trial of treatments for COVID-19. He has published more than 500 manuscripts and book chapters, and has been cited more than 117 000 times. He is the founding chair of the International Forum of Acute Care Trialists (InFACT) – a global network of 37 investigator-led critical care clinical research groups. He is past-chair of the International Sepsis Forum, past-President of the Surgical Infection Society, past Secretary-General of the World Federation of Societies of Intensive and Critical Care Medicine, and past-chair of the Canadian Critical Care Trials Group. He is current co-Chair of a WHO Working Group on the Clinical Characterization and Management of COVID-19. He has given more than 1200 invited lectures at more than 500 meetings around the world, and is an Associate Editor of the journals Critical Care Medicine and Critical Care.

Djillali Annane

Djillali Annane is a Professor in Medicine at University Paris Saclay-UVSQ. He is specialized in intensive care medicine, cardiology and pharmacology. He is the Director of the General ICU Department at Raymond Poincaré Hospital, GHU APHP, and the Director of Team 1 LARENE in the Infection & Inflammation U1173 University Paris Saclay & INSERM lab. He is Dean of the School of Medicine Simone Veil at University Paris Saclay-UVSQ. He is the Past President of the French Society of Intensive Care Medicine. Djillali Annane is a leading researcher in the field of sepsis. He has contributed to several international and multidisciplinary guidelines. He has authored some peer-reviewed articles and about 150 book chapters. He is the founder and past coordinator of the CRICS-TRIGGERSEP network, a sepsis network labelled by F-CRIN, the French branch of the European Clinical Research Infrastructure Network, funded by the European Commission.

Yaseen Arabi

Dr Arabi obtained his internal medicine training and Chief Medical Resident experience at Wayne State University, Detroit, USA (1992–1995). He obtained pulmonary and critical care training at the University of Wisconsin, Madison, USA (1995–1998). He is currently the Chairman of the Intensive Care Department, the Medical Director, Respiratory Services; and Professor, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Saudi Arabia. He is currently the Principal Investigator/Co-Investigator on several multicentre randomized controlled trials. He has been involved in MERS and COVID-19 research. He has contributed to more than 300 publications, including articles in leading medical journals. He is currently a Section Editor for Intensive Care Medicine and on the editorial board of several journals. He received multiple grants and awards including the Barry A Shapiro Memorial Award for Excellence in Critical Care Management, Society of Critical Care Medicine, USA (2011).
Ivana Blazic

Ivana Blazic is a board certified radiologist with a doctoral degree in radiology, subspecialized in oncology. Currently, she is MRI section head in the Clinical Hospital Centre Zemun in Belgrade. Dr. Blazic has been providing technical support to WHO on several projects, including a WHO rapid advice guide on the use of imaging in COVID-19. As a member of the International Society of Radiology (ISR) Communications Working Group, she also acts as an expert for ISR. She has experience in teaching, and clinical and research work in different countries and continents, including the Memorial Sloan Kettering Cancer Centre, New York, USA; Imperial College London, UK; University Hospital of Antwerp, Belgium; Hacettepe University Hospital, Ankara, Turkey; and Seoul National University Hospital, Seoul, Republic of Korea. As an invited speaker, she gave more than 25 lectures at international meetings. She is an active member of nine national and international professional societies. She has contributed to more than 50 journal publications in: Radiology, European Radiology, Journal of Clinical Oncology, JAMA Surgery and British Journal of Radiology.

Nigel Curtis

Professor Curtis did his undergraduate medical degree at the University of Cambridge and clinical training at St Mary’s Medical School, University of London. He undertook his laboratory training at Imperial College London St Mary’s Campus, where he completed a PhD investigating the role of bacterial superantigen toxins in Kawasaki disease and in staphylococcal and streptococcal toxic shock syndrome. His specialist training in infectious diseases included working at the Great Ormond Street Hospital for Sick Children and a Fellowship at the British Columbia Children’s Hospital. He has also worked for periods in Gambia, Zimbabwe and South Africa. Professor Curtis’ research focuses on improving the diagnosis, treatment and prevention of infectious diseases in children, combining clinical research and trials with laboratory immunology studies. He has been the lead investigator on numerous trials including the MIS BAIR Trial, a randomized controlled trial of neonatal BCG vaccination to investigate the immunomodulatory heterologous (“non-specific”) effects of this vaccine, including its ability to prevent infections, allergic disease and asthma. He is the Chief Principal Investigator of the BRACE Trial, a randomized controlled trial of BCG vaccination to reduce the impact of COVID-19 in health care workers that is recruiting over 10,000 participants in three continents worldwide.

Anne von Gottberg

Anne von Gottberg is currently the laboratory lead for the Centre for Respiratory Diseases and Meningitis at the National Institute for Communicable Diseases, Johannesburg, South Africa and Associate Professor within the School of Pathology, Faculty of the Health Sciences, University of the Witwatersrand, Johannesburg; and Honorary Professor, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town. She leads a laboratory team responsible for reference diagnostics for respiratory and meningeal pathogens nationally and regionally. The laboratory is the regional reference laboratory for the WHO Vaccine-preventable Invasive Bacterial Diseases (VP-IBD) Coordinated Global Surveillance Network for the southern African region; a national influenza centre; and a WHO RSV and SARS-CoV-2 reference laboratory. Her main interests include surveillance for meningitis and respiratory pathogens, assessing vaccine effectiveness where relevant. She has authored or co-authored more than 170 articles in peer-reviewed journals. In addition, she supervises a number of Masters and PhD students. Dr. von Gottberg obtained her MBCh and PhD at the University of the Witwatersrand, and trained for her specialization in clinical microbiology at the National Health Laboratory Service (former South African Institute for Medical Research) and at the University of the Witwatersrand.
Beverley Hunt

Professor of Thrombosis & Haemostasis at King's College London; Consultant in the Thrombosis & Haemophilia Centre at Guy's & St Thomas NHS Foundation Trust; and Clinical Lead in Haematological Sciences at Viapath LLP, Professor Hunt is founder and Medical Director of Thrombosis UK and Chair of the Steering Group of World Thrombosis Day. She was awarded an OBE in the Queen’s birthday honours list in 2019 for services to medicine. In the COVID-19 pandemic she has become an international expert on thrombosis and coagulopathy in COVID-19 patients, and has given over 60 webinars including being an expert witness for the British House of Lords Science and Technology Committee. She has also given numerous media interviews including working with BBC News.

Nathalie McDermott

Nathalie McDermott is an academic clinical lecturer at King’s College London funded by the UK National Institute for Health Research (NIHR). She works clinically as a paediatric infectious diseases registrar, but her research background is in epidemic and pandemic diseases. Her PhD, undertaken at Imperial College London, investigated genetic susceptibility to outcome from Ebola virus disease in Sierra Leone. This research also involved determining disease transmission dynamics in rural and urban communities, and understanding outcomes from Ebola such as asymptomatic infection and post-Ebola conditions in Ebola survivors. She has cared for children with multi-system inflammatory syndrome related to COVID-19 and is also personally suffering from a Post COVID-19 condition, so brings her own personal insights of the condition as well as clinical expertise.

Piero Olliaro

Professor Piero Olliaro has a postgraduate degree in infectious diseases (Pavia, Italy), MA (Oxford, UK), PhD (Pavia), HDR (Habilitation à Diriger les Recherches, Grenoble, FR). He is Membre Etranger de l’Académie de Médecine (French Academy of Medicine), France and was granted the Newton-Abraham Professorship in 2014–2015 at Lincoln College, University of Oxford. He is Full Professor and Chair of Infectious Diseases of Poverty at the University of Oxford, UK and Director of Science with the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). His current primary areas of work is epidemic preparedness and response, including clinical research in COVID-19, plague, and Lassa fever. Other research subjects are neglected tropical diseases and diagnostics. Previously, he led intervention and implementation at the Special Programme on Research and Training in Tropical Diseases (TDR), WHO, Geneva. He is author of 370 peer-reviewed articles and numerous other documents.

Marco Rizzi

See Speakers

Regis Goulart Rosa

See Speakers
Manu Shankar-Hari
NIHR Clinician Scientist and Professor of Critical Care Medicine, Guy’s and St Thomas’ Hospital NHS Foundation Trust, London, UK. Shankar-Hari group’s research explores ways to improve outcomes in adult critically ill patients with sepsis and with ARDS, by linking the illness immunobiology with novel interventional trial designs. His focussed research themes include: immunobiology – exploring adaptive immune system changes in critically ill patients (e.g. sepsis, ARDS); and COVID-19 immunology in adults and in children in PIMS-TS.

Elizabeth Semper
Elizabeth Semper is President of the COVID Persistente España Association. She is a graduate in Educational Pedagogy Sciences from UCM. As a teacher she specializes in integrated teaching methods and didactic developments and has wide experience in establishing and maintaining collaborative, productive work environments, administration and management.
**Chair**
Charu Kaushic

Charu Kaushic is the Scientific Director of the Canadian Institutes of Health Research (CIHR) Institute of Infection and Immunity. Dr Kaushic is also a tenured Full Professor in the Department of Medicine in McMaster University, Hamilton, Canada. She serves as a Chair of GloPID-R, a global consortium of funders in pandemic preparedness and emergency response research. She also represents Canada on the JPIAMR Management Board. Dr Kaushic has a PhD in Immunology and did her post-doctoral training in mucosal immunology. Since her faculty appointment in McMaster in 2002, she has done extensive teaching and training in immunology and built an interdisciplinary research programme in women’s reproductive health, specifically basic, clinical and translational research examining susceptibility and immune responses to sexually transmitted viruses, HIV-1 and HSV-2.

---

**Oved Amitay**

Oved Amitay is the Chief Executive Officer at the Solve ME/CFS Initiative, dedicated to making myalgic encephalomyelitis (also known as chronic fatigue syndrome or ME/CFS) understood, diagnosed and treatable. Oved has dedicated most of his professional career to the development of life-changing therapeutic options for people affected by rare genetic diseases. He has extensive engagements with health care systems and patient advocacy organizations around the world, forging collaborations for patient registries and natural history studies for drug development. One of the Solve ME/CFS Initiative’s flagship programmes is the You + ME Registry and Biobank (https://youandmeregistry.com/), an online clinical study of individuals living with ME/CFS, people with long COVID, and control volunteers. Responding to the current urgent need and recognizing the similarities between ME/CFS and what many people with long COVID are experiencing, Oved and his organization are building a network of patient-advocates, scientists and disease experts to collaborate and share their collective knowledge to transform our understanding and treatment of post-viral illness.

---

**Ettore Beghi**

Ettore Beghi is Head of the Laboratory of Neurological Disorders (since 1996) at the Institute Mario Negri IRCCS, Milan, Italy, and former Research Fellow at the Department of Medical Statistics and Epidemiology, Mayo Clinic, Rochester (1982–1983). He is Associate Editor of Epilepsia Open and Neuroepidemiology, and member of the Editorial Board of the journals Clinical Neurology & Neurosurgery, Clinical Drug Investigation, ALS & Frontotemporal Dementia, and referee of more than 20 journals. He holds past or current member (or chair) of the following scientific societies/groups: Mayo Alumni Association, Italian Neurological Society (INS), Italian League against Epilepsy (LICE), Neuroepidemiology Section of the INS, Neuroepidemiology Section of the American Academy of Neurology (AAN), Commission on the Epidemiology of Epilepsy of the International League Against Epilepsy (ILAE), Commission “Epilepsy, Risks, and Insurance” of the International Bureau of Epilepsy (IBE), ILAE Commission “Antiepileptic Drugs”, Cochrane Epilepsy Group, ILAE Commission on the Burden of Epilepsy, International Subcommittee of the AAN, Course Director at the AAN, European ALS registry, Italian Epilepsy Study Group, Epilepsy and Quality of Life Study group, Italian Drug Agency (AIFA) (consultant), European Medicines Agency (consultant), Fellow of the AAN (FAAN) and European Academy of Neurology (EAN), Co-Chair of the Epidemiology Panel of the EAN, Past President of the LICE, member of the ILAE Task Forces on the Global Cost of Epilepsy, Epilepsy and Driving and Epilepsy in the Elderly.
Francesco Castelli
Francesco Castelli is Professor of Infectious Diseases and Head of the University Division of Infectious and Tropical Medicine at the University of Brescia, Italy and ASST Spedali Civili of Brescia. Professor Castelli presently acts as Deputy Rector of the University of Brescia and the Chair of the Department of Medicine of the ASST Spedali Civili of Brescia. He is the holder of the UNESCO Chair “Training and empowering human resources for health development in resource-limited countries”. He is a member of the Scientific and Technical Committee for HIV/AIDS, Italian Ministry of Health, and acted as Director of the WHO Collaborating Centre on HIV/TB Co-infection and TB elimination strategies 2001–2015. His major fields of scientific interest are infectious and tropical diseases, migration medicine and imported infections, global health and chronic viral infections in both industrialized and developing countries. He has published more than 400 papers in peer-reviewed journals. He was awarded the title of Knight of the Order of Merit of the Italian Republic in 2011 and included in the list of top Italian scientists in 2013. Of note, the ASST Spedali Civili of Brescia admitted more than 3500 COVID-19 patients during the recent pandemic. Professor Castelli is a member of the Technical and Scientific Committee of the Region Lombardy for the COVID-19 pandemic.

Andrea Fiorillo
Andrea Fiorillo is Full Professor of Psychiatry in Naples, Italy, at the University of Campania “L. Vanvitelli”. He is currently a board member of the European Psychiatric Association (EPA) and Secretary for Scientific Sections. He is Chair of the Section on Education in Psychiatry of the World Psychiatric Association (WPA), member of the WPA Operational Committee on Education, Honorary Member of the WPA, and President of the Italian Society for Social Psychiatry. He is Editor in Chief of European Psychiatry. He is author of more than 250 scientific papers in international peer-reviewed journals. He is editor of more than 10 books and several chapters in the field of mental health. His main research interests include clinical and social psychiatry, academic psychiatry, psychiatric epidemiology, prevention of mental disorders, and promotion of physical and mental health in people with severe mental illnesses.

Sarah Geline
Sarah Geline trained as a registered nurse and practised in New York City before moving to Cape Town, South Africa, where she currently lives with her husband and young triplet daughters. She has been recovering from a suspected COVID-19 infection since April 2020.

Laura Gochicoa
Associate Professor in Respiratory Physiology at the National Institute of Respiratory Diseases of México, Universidad Nacional Autónoma de México, México City, Mexico.
Lori Newman

Since June 2018, Dr Lori Newman has been a medical officer for the Enteric and Sexually Transmitted Infections (STI) Branch at the United States National Institutes for Health (NIH) in Rockville, Maryland. Since February 2020 she has been part of the NIH COVID-19 response team in the areas of post-acute sequelae, serology, and review of proposals for clinical trials of epidemiology, therapeutics, vaccines, and diagnostics. She is also a United States Public Health Service (PHS) officer, and was recently deployed to California/Mexican border and the Navajo Nation as part of the PHS clinical COVID-19 response. She provides outpatient acute care at Fort Belvoir Family Medicine Clinic. She received a BA in Geography at Dartmouth College in 1990. She went to medical school at University of California San Francisco in 1995. She completed residency in Family Medicine at University of Washington in 1998. She spent 2 years in Mozambique working for the Finnish Development Agency before moving to Atlanta where she provided primary care at DeKalb Community Health Center. She joined the PHS and the CDC through the Epidemic Intelligence Service in 2001 with the Division of STD Prevention. From 2009–2015, CDC seconded her to the WHO where she led elimination of congenital syphilis and STI surveillance. From 2015–2018, she worked for the President’s Emergency Plan for AIDS Relief (PEPFAR) as HIV Strategic Information Advisor in Phnom Penh, Cambodia.

Jose Luis Peñalvo

José L Peñalvo is Professor of Public Health and the Head of Non-Communicable Diseases Unit at the Institute of Tropical Medicine in Antwerp, Belgium. He has a strong background in clinical research, epidemiological methods and expertise in chronic disease epidemiology evidence synthesis, and quantifying and modelling health impacts, and effectiveness of population-based strategies to reduce chronic disease burden. Dr Peñalvo is an expert in the use of large-scale clinical data such as electronic medical records and registry data, as well as epidemiological databases to support effectiveness studies. He is currently leading research efforts to use real-world data to understand and mitigate the increased fatality of COVID-19 among chronic patients. Dr Peñalvo is the coordinator of unCoVer, a H2020 project dedicated to the pooled analysis of real-world data (e.g. electronic health records, patient registers) generated through the provision of care to COVID-19 patients from 29 partners in 14 countries in Europe, and internationally.

Simone Piva

See Speakers

Saniya Sabzwari

Saniya Sabzwari is an Associate Professor in the Department of Family Medicine at the Aga Khan University, Karachi, Pakistan. She is a Fellow of the American Academy of Family Physicians. Her area of special interest is geriatrics. She established the first ever out-patient geriatric service in Pakistan and also developed geriatric undergraduate and postgraduate training programmes at the Aga Khan University in 2008. Her research focuses on community geriatrics in which she has published several papers. She is part of the Geriatric Special Interest Group for the World Organization of Family Doctors.
Natalie Strub-Wourgaft

Dr Nathalie Strub-Wourgaft joined the Drugs for Neglected Diseases initiative (DNDi) in 2009 and is currently Director of NTDs and ANTICOV Lead. She has over 30 years' experience in R&D. As Director of NTDs since 2018, Dr Strub-Wourgaft provides strategic and technical oversight to a wide portfolio of R&D and access plans for therapeutic areas covering sleeping sickness, Chagas disease, cutaneous and visceral leishmaniasis, filaria, and mycetoma. In 2018, through an international public and private partnership including scientific platform from Africa, DNDi developed Fexinidazole, its first new chemical entity registered from its portfolio. Since March 2020, Nathalie leads DNDi's response to COVID-19, as Coordinator of the ANTICOV Study Consortium and one of the initiators of the COVID-19 clinical research coalition. She is involved in several working groups dedicated to therapeutics for COVID-19, with a specific focus on LMIC needs and settings. Prior to her current appointment, Dr Strub-Wourgaft created and held the Medical Director position at DNDi, where she notably developed the organization's quality, pharmacovigilance and regulatory activities. Prior to DNDi, Dr Strub-Wourgaft served as Clinical Development Director at Trophos, and held many related roles within Pfizer, Lundbeck and Aspreva. Dr Strub-Wourgaft graduated as Medical Doctor from Necker Hospital, Université René Descartes in Paris in 1983. She has co-authored several scientific publications in peer-reviewed journals.

Miroslav Zvolský

Miroslav Zvolský graduated the Charles University in Prague in 2006. He worked in the Department of Medical Informatics at the Czech Academy of Sciences in projects dealing with the formalization of medical knowledge. In 2012, he moved to the Institute of Health Information and Statistics of the Czech Republic to manage the National Cancer Registry data collection. Since 1 January 2016, he has held the position of Head of the Clinical Classification Department, where he focuses on the implementation and support of the International Classification of Diseases in the Czech Republic. He is a co-chair of the Morbidity Reference Group of WHO Family of International Classification (WHO-FIC) Network since 2020 and the Head of the Czech WHO-FIC Collaboration Centre.